Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
Stocks · News reference
PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
https://www.theinformation.com/articles/trump-administration-plans-move-ai-testing-agency-officials-white-house
Cloud capital (Suzhou, Anhui) announced significant progress on its 2026 initiatives, including expansion of intelligent computing centers with over 6,000 P capacity expected by year-end. The company has deployed an industrial internet platform connecting 487 enterprises and is building green computing infrastructure while exploring public data monetization to transform Suzhou from a traditional agricultural city into a key computing power hub integrated with the Yangtze River Delta digital economy.